JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Predictive factors for invasive cervical cancer in patients referred for colposcopy after abnormal cervical smear screening
Abstract
Aims: To evaluate the clinical and pathological factors associated with invasive cervical cancer in patients referred for colposcopy after abnormal cervical smear screening.
Methods: This retrospective cohort study included 5,033 patients aged 18 years and older who underwent colposcopic evaluation between September 2019 and December 2025 at a tertiary gynecologic oncology center after an abnormal cervical smear result. Patients were classified according to the presence or absence of histopathologically documented invasive cervical cancer based on the highest-grade diagnosis available during follow-up. Age, smear category, human papillomavirus (HPV) status, colposcopic biopsy findings, endocervical curettage (ECC) findings, and final pathology results were analyzed. Logistic regression analysis was performed to identify variables independently associated with invasive cervical cancer.
Results: Invasive cervical cancer was identified in 32 of 5,033 patients (0.64%). Patients with invasive cancer were significantly older than those without invasive disease (49.8 ± 11.0 vs 41.8 ± 11.3 years, p=0.00026). High-risk smear findings were more common in the invasive cancer group than in the non-invasive group (46.9% vs 6.1%, p<0.001). Invasive cancer was detected in 4.34% of patients with high-grade squamous intraepithelial lesion or worse (HSIL+) on colposcopic biopsy versus 0.07% of those with non-HSIL biopsy findings (OR 65.99, 95% CI 20.04-217.25, p<0.001). Similarly, invasive cancer was identified in 11.6% of patients with HSIL+ on ECC compared with 0.31% of those with non-HSIL ECC results (OR 42.47, 95% CI 20.76-86.88, p<0.001). In multivariable analysis, older age, high-risk smear findings, HSIL+ on colposcopic biopsy, and HSIL+ on ECC remained significantly associated with invasive cervical cancer. Some invasive cancers were identified only in final pathology specimens, suggesting that preoperative assessment may underestimate invasive disease in a subset of patients.
Conclusion: Invasive cervical cancer was uncommon but clinically relevant in patients referred for colposcopy after abnormal cervical smear screening. Older age, high-risk smear findings, HSIL+ on colposcopic biopsy, and HSIL+ on ECC were the variables most strongly associated with invasive disease. An integrated interpretation of cytology, HPV status, biopsy, ECC, and clinical context may improve recognition of patients at increased risk for invasive cervical cancer.

Keywords : Cervical cancer, colposcopy, cytology, HPV, endocervical curettage, invasive disease

Download Article


1. Viveros-Carreño D, Fernandes A, Pareja R. Updates on cervical cancer prevention. Int J Gynecol Cancer. 2023;33(3):394-402. doi:10.1136/ijgc-2022-003703
2. Singh D, Vignat J, Lorenzoni V, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health. 2023;11(2):e197-e206. doi:10.1016/S2214-109X(22)00501-0
3. Gopalkrishnan K, Karim R. Addressing global disparities in cervical cancer burden: a narrative review of emerging strategies. Curr HIV/AIDS Rep. 2025;22(1):18. doi:10.1007/s11904-025-00727-2
4. Wang R, Pan W, Jin L, et al. Human papillomavirus vaccine against cervical cancer: opportunity and challenge. Cancer Lett. 2020;471:88-102. doi:10.1016/j.canlet.2019.11.039
5. Rayner M, Welp A, Stoler MH, Cantrell LA. Cervical cancer screening recommendations: now and for the future. Healthcare (Basel). 2023; 11(16):2273. doi:10.3390/healthcare11162273
6. Pangarkar MA. The Bethesda System for reporting cervical cytology. Cytojournal. 2022;19:28. doi:10.25259/CMAS_03_07_2021
7. World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. 2nd ed. Geneva: World Health Organization; 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK572321/
8. Ouh YT, Park JJ, Kang M, et al. Discrepancy between cytology and histology in cervical cancer screening: a multicenter retrospective study (KGOG 1040). J Korean Med Sci. 2021;36(24):e164. doi:10.3346/jkms.2021.36.e164
9. McBride AA. Human malignancies associated with persistent HPV infection. Oncologist. 2024;29(6):457-464. doi:10.1093/oncolo/oyae071
10. Taghavi K, Zhao F, Downham L, Baena A, Basu P. Molecular triaging options for women testing HPV positive with self-collected samples. Front Oncol. 2023;13:1243888. doi:10.3389/fonc.2023.1243888
11. Wentzensen N, Walker JL, Gold MA, et al. Multiple biopsies and detection of cervical cancer precursors at colposcopy. J Clin Oncol. 2015;33(1):83-89. doi:10.1200/JCO.2014.55.9948
12. Li Y, Gong YX, Wang Q, et al. Optimizing the detection of occult cervical cancer: a prospective multicentre study in China. Int J Womens Health. 2021;13:1005-1015. doi:10.2147/IJWH.S329129
13. Desai KT, Hansen N, Rodriguez AC, et al. Squamocolumnar junction visibility, age, and implications for cervical cancer screening programs. Prev Med. 2024;180:107881. doi:10.1016/j.ypmed.2024.107881
14. Perkins RB, Guido RS, Castle PE, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020;24(2):102-131. doi:10.1097/LGT.0000000000000525 Erratum in: J Low Genit Tract Dis. 2020;24(4):427. doi:10.1097/LGT.0000000000000563
15. Yu L, Majerciak V, Zheng ZM. HPV16 and HPV18 genome structure, expression, and post-transcriptional regulation. Int J Mol Sci. 2022; 23(9):4943. doi:10.3390/ijms23094943 Erratum in: Int J Mol Sci. 2022; 23(14):7903. doi:10.3390/ijms23147903
16. Clarke MA, Wentzensen N, Perkins RB, et al. Recommendations for use of p16/Ki67 dual stain for management of individuals testing positive for human papillomavirus. J Low Genit Tract Dis. 2024;28(2):124-130. doi:10.1097/LGT.0000000000000802 Erratum in: J Low Genit Tract Dis. 2024;28(3):316. doi:10.1097/LGT.0000000000000825
17. Massad LS, Perkins RB, Naresh A, et al. Colposcopy standards: guidelines for endocervical curettage at colposcopy. J Low Genit Tract Dis. 2023;27(1):97-101. doi:10.1097/LGT.0000000000000710
18. Liu Q, Yang J, Cheng H, Shu C, Tang Y, Zhao J. A clinical prediction model for pathologic upgrade to invasive carcinoma following conization of cervical high-grade squamous intraepithelial lesions. Cancer Med. 2025;14(1):e70540. doi:10.1002/cam4.70540
Article available in :
Volume 4, Issue 3, 2026
Page : 80-85
https://doi.org/10.51271/JCHOR-0087
Article Information
Received : 02 May 2026
Accepted : 03 Haz 2026
Published : 08 Ağu 2026
Corresponding Author :

Yeşim Özkaya Uçar: Department of Gynecologic Oncology, Ankara Bilkent City Hospital, Ankara, Turkiye

[email protected]
Citation : Özkaya Uçar Y, Aytekin O, Kuzu AE, et al. Predictive factors for invasive cervical cancer in patients referred for colposcopy after abnormal cervical smear screening. J Curr Hematol Oncol Res. 2026;4(3):80-85. doi:10.51271/JCHOR-0087

Read: 9
Download : 5
Cited: 0
_Footer